Back
Treatment Considerations in Relapsed/Refractory NPM1-Mutant Acute Myeloid Leukemia
Dr. Anand Patel from the University of Chicago and Dr. Cecilia Arana Yi from Mayo Clinic Phoenix discussed the evolving treatment landscape for relapsed/refractory NPM1-mutated acute myeloid leukemia (AML). The conversation emphasized comprehensive disease re-characterization at relapse, including repeated molecular testing, fitness assessment, and transplant candidacy evaluation to guide treatment selection between intensive chemotherapy, lower-intensity approaches, or targeted therapies. Key discussions centered on menin inhibitors (revumenib and ziftomenib) as breakthrough targeted therapies, demonstrating 23% to 25% complete remission rates in heavily pretreated patients with manageable toxicity profiles. The speakers highlighted differentiation syndrome as the primary adverse effect requiring proactive monitoring and cytoreductive strategies using hydroxyurea for high white blood cell counts.
Treatment Considerations in Relapsed/Refractory NPM1-Mutant Acute Myeloid Leukemia
Episodes
All
All
Dr. Patel explains the biological rationale for targeting the menin-KMT2A pathway in NPM1-mutated AML, describing breakthrough discoveries demonstrating menin's role in leukemogenesis for NPM1-mutated and KMT2A-rearranged acute leukemia.
Dr. Patel discusses clinical trial efficacy data from KOMET-001 evaluating ziftomenib safety and preliminary efficacy in R/R NPM1-mutated AML and AUGMENT-101 results for revumenib.
Dr. Arana Yi discusses menin inhibitor impact on traditional chemotherapy utilization in R/R NPM1-mutated disease. Current options favor targeted therapies versus salvage chemotherapy when available, with treatment selection considering prior therapy types, particularly venetoclax-based combination history.
Dr. Arana Yi addresses common side effects beyond differentiation syndrome, including QT prolongation and cytopenias described in KOMET-001 and AUGMENT-101 clinical trials. She inquires about differences between ziftomenib and revumenib regarding QT prolongation and cytopenia management approaches.
Dr. Patel shifts focus from R/R to frontline settings, highlighting menin inhibitor investigation in newly diagnosed AML as exciting development areas.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
3
The OncFive: Top Oncology Articles for the Week of 8/16
4
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
5